Minerva Surgical analyst ratings
Minerva Surgical analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2022 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 05/12/2022 | 123.05% | Piper Sandler | $12 → $6 | Maintains | Overweight |
| 05/12/2022 | 160.22% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 03/09/2022 | 346.1% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 12/03/2021 | 346.1% | SVB Leerink | $17 → $12 | Maintains | Outperform |
| 11/16/2021 | 531.97% | SVB Leerink | → $17 | Initiates Coverage On | → Outperform |
| 11/16/2021 | 457.62% | UBS | → $15 | Initiates Coverage On | → Buy |
| 11/16/2021 | 420.45% | JP Morgan | → $14 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 531.97% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/10/2022 | — | 摩根大通 | 降級 | 超重 → 體重不足 | |
| 05/12/2022 | 123.05% | 派珀·桑德勒 | 12 美元 → 6 美元 | 維護 | 超重 |
| 05/12/2022 | 160.22% | SVB Leerink | 8 美元 → 7 美元 | 維護 | 跑贏大盤 |
| 03/09/2022 | 346.1% | 派珀·桑德勒 | 17 美元 → 12 美元 | 維護 | 超重 |
| 2021 年 3 月 12 日 | 346.1% | SVB Leerink | 17 美元 → 12 美元 | 維護 | 跑贏大盤 |
| 11/16/2021 | 531.97% | SVB Leerink | → 17 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/16/2021 | 457.62% | 瑞銀（UBS） | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/16/2021 | 420.45% | 摩根大通 | → 14 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 11/16/2021 | 531.97% | 派珀·桑德勒 | → 17 美元 | 啓動覆蓋範圍開啓 | → 超重 |
Minerva Surgical Questions & Answers
密涅瓦外科問題與解答
The latest price target for Minerva Surgical (NASDAQ: UTRS) was reported by JP Morgan on August 10, 2022. The analyst firm set a price target for $0.00 expecting UTRS to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
摩根大通於2022年8月10日公佈了密涅瓦外科（納斯達克股票代碼：UTRS）的最新目標股價。該分析公司將目標股價設定爲0.00美元，預計UTRS將降至12個月內（可能下跌-100.00％）。去年有9家分析公司公佈了評級。
The latest analyst rating for Minerva Surgical (NASDAQ: UTRS) was provided by JP Morgan, and Minerva Surgical downgraded their underweight rating.
密涅瓦外科（納斯達克股票代碼：UTRS）的最新分析師評級由摩根大通提供，密涅瓦外科下調了其減持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Minerva Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Minerva Surgical was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與密涅瓦外科的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。密涅瓦外科的最後一次評級是在2022年8月10日提交的，因此您應該預計下一個評級將在2023年8月10日左右公佈。
While ratings are subjective and will change, the latest Minerva Surgical (UTRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Minerva Surgical (UTRS) is trading at is $2.69, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的密涅瓦外科（UTRS）評級下調，目標股價爲0.00美元至0.00美元。密涅瓦外科（UTRS）目前的交易價格爲2.69美元，超出了分析師的預期區間。